Indaptus Competitors
| INDP Stock | USD 1.77 -0.03 -1.67% |
Indaptus Therapeutics vs Azitra Correlation Summary
Poor diversification
The correlation between INDP and AZTR is 0.72, which Macroaxis classifies as Poor diversification for the selected horizon. Used correctly, the chart helps investors judge whether adding the second position genuinely diversifies the first.
Moving against Indaptus Stock
The concept of mean reversion suggests that Indaptus Therapeutics' price will eventually return toward its long-run average. High prices may deter value investors, while unusually low prices often attract buyers who anticipate a recovery.
Indaptus Therapeutics Competition Correlation Matrix
Correlation analysis between Indaptus Therapeutics and its competitors helps investors understand whether diversification is real or only superficial inside the same peer group. This matrix is most informative when investors want to know whether adding another peer would improve diversification, increase crowding, or leave total risk largely unchanged.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Indaptus Stock performing well and Indaptus Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Indaptus Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| SLXN | 4.15 | -0.69 | 0.00 | -0.31 | 0.00 | 10.98 | 29.74 | |||
| REVB | 4.10 | -1.57 | 0.00 | -0.85 | 0.00 | 5.56 | 34.09 | |||
| PBM | 5.62 | -1.75 | 0.00 | -1.05 | 0.00 | 9.96 | 48.52 | |||
| NKGN | 15.31 | 4.97 | 0.15 | -0.94 | 12.78 | 35.14 | 298.33 | |||
| GTBP | 4.42 | -0.51 | 0.00 | -2.13 | 0.00 | 8.33 | 37.01 | |||
| ATXI | 8.88 | -0.36 | 0.00 | -0.28 | 0.00 | 22.22 | 122.38 | |||
| PTIX | 8.67 | -1.27 | 0.00 | 8.06 | 0.00 | 19.57 | 58.73 | |||
| SLRX | 6.68 | -1.98 | 0.00 | 1.66 | 0.00 | 16.00 | 61.05 | |||
| LIPO | 7.36 | -0.15 | 0.00 | -0.15 | 0.00 | 18.75 | 94.73 | |||
| AZTR | 4.69 | -0.94 | 0.00 | -0.56 | 0.00 | 7.14 | 40.00 |
Peer Comparison: Net Income
Net income is one of the most important fundamental items in finance. It plays a large role in Indaptus Therapeutics financial statement analysis. It represents the amount of money remaining after all of Indaptus Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Compare Indaptus Therapeutics and related stocks such as Biomotion Sciences, Revelation Biosciences, and Psyence Biomedical Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SLXN | -195.9 K | -195.9 K | -195.9 K | -195.9 K | -195.9 K | -195.9 K | -195.9 K | -195.9 K | -195.9 K | -195.9 K | -195.9 K | -755.2 K | -3.2 M | -4.9 M | -16.4 M | -14.8 M | -14.1 M |
| REVB | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 6.2 M | 8.8 M | 16.3 M | 27.6 M | -3.6 K | -136.4 K | -12 M | -10.8 M | -120.3 K | -15 M | -8.9 M | -8.5 M |
| PBM | 8.2 M | 8.2 M | 8.2 M | 8.2 M | 8.2 M | 8.2 M | 8.2 M | 8.2 M | 8.2 M | 8.2 M | 8.2 M | 8.2 M | 8 M | -51.2 M | 1 M | 910.6 K | 956.1 K |
| GTBP | 150 K | -3.7 M | -5.2 M | -501 K | -23.5 M | -21.5 M | 9.8 M | -144.2 M | -259.2 M | -38.6 M | -28.3 M | -58 M | -20.9 M | -7.6 M | -13.2 M | -28.4 M | -26.9 M |
| PTIX | -476 K | -476 K | -1 M | -1.1 M | -1.1 M | -476 K | -2.3 M | -2.3 M | -2.6 M | -1.8 M | -2.5 M | -4.5 M | -3.6 M | -5 M | -5.5 M | -5.2 M | -5.4 M |
| LIPO | -61.8 K | -61.8 K | -61.8 K | -61.8 K | -61.8 K | -61.8 K | -61.8 K | -61.8 K | -61.8 K | -61.8 K | -61.7 K | -1.9 M | -2.6 M | -4.6 M | -5 M | -4.5 M | -4.3 M |
| AZTR | -8.9 M | -8.9 M | -8.9 M | -8.9 M | -8.9 M | -8.9 M | -8.9 M | -8.9 M | -8.9 M | -8.9 M | -8.9 M | -8.9 M | -10.7 M | -11.3 M | -9 M | -11 M | -11.5 M |
Indaptus Therapeutics Competitive Analysis
Indaptus Therapeutics' competitive standing becomes clearer when measured alongside Biomotion Sciences, Revelation Biosciences, and Psyence Biomedical. A 4.0 M market capitalization places Indaptus Therapeutics firmly within this peer set. Indaptus Therapeutics posts a -317.98% return on equity, reflecting current earnings headwinds. Return on equity favors Indaptus Therapeutics at -317.98%, well ahead of Biomotion Sciences at -771.23%. On pure scale, Revelation Biosciences is the bigger entity with market caps of 4.6 M versus 4.0 M. Psyence Biomedical leads with -74.29% return on equity versus -317.98% for Indaptus Therapeutics.| Better Than Average | Worse Than Peers | View Performance Chart |
Peer Performance Charts
How to Analyze Indaptus Therapeutics Against Peers
Indaptus Therapeutics' peer analysis compares Indaptus Therapeutics with related companies to put valuation, quality, and risk metrics in context. This helps determine whether recent performance is company-specific or broadly sector-driven. A practical workflow includes:- Set a relevant peer group: Include direct competitors and close alternatives with comparable business exposure.
- Benchmark core financials: Compare profitability, growth, capital structure, and cash flow quality.
- Check valuation dispersion: Review whether Indaptus Therapeutics trades at a premium or discount versus peers and why.
- Evaluate risk profile: Compare volatility, drawdowns, and correlation to avoid false diversification assumptions.
- Document the thesis: Record where Indaptus Therapeutics leads or lags and what catalysts could close or widen the gap.